Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs IAC/Interactivecorp (PPLI) Price & Performance

Citius Pharmaceuticals IncTrade
IAC/InteractivecorpTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs IAC/Interactivecorp — how do they compare? Citius Pharmaceuticals Inc trades at $0.75 (market cap $20.01M), while IAC/Interactivecorp trades at $40.77 (market cap $2.97B). The key difference: IAC/Interactivecorp is far larger — about 148.4× Citius Pharmaceuticals Inc's market cap, and IAC/Interactivecorp is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

CTXRPPLI
Market Cap
$20.01M$2.97B
Sector
HealthMedia
52-Week High
$1.82$47.62
52-Week Low
$0.48$31.52
Enterprise Value
$16.23M$3.28B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.

The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.

IAC/Interactivecorp

PPLI trades at $40.88, up 0.54% with bearish technical signals but strong analyst support. The stock shows mixed fundamentals with Q2 2026 earnings beat of $6.77 EPS versus -$0.40 expected, though revenue declined to $2.39B in 2025. Valuation metrics appear attractive with P/E of 6.76 and P/B of 0.59. Recent news highlights digital growth and MGM investment gains driving profitability.

Investment outlook balances deep value against operational challenges. The 69% buy rating and $60.50 price target suggest 48% upside, but negative cash flow and volatile earnings pose risks. Key catalysts include asset monetization and MGM stake value realization, while execution risks and debt levels require monitoring.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About IAC/Interactivecorp

IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.

Read more on PPLI